Due to the DNA repair defect, BRCA1/2 deficient tumor cells are more sensitive to PARP
inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several PAPRi …

… PARP and PARP inhibitors and the results from the clinical studies that investigated the effects
of the FDA-approved PARP inhibitors … research progress on PARP inhibitors, their safety, …

… PARP inhibitor that is also the most potent PARP inhibitor yet reported. Talazoparib can block
the activity of the PARP enzyme while trapping PARP … performance of PARP inhibitors, and …

… of the mechanism by which PARP inhibitors mediate their anti-cancer capacity but may
also increase the subset of patients treated with PARP inhibitors. Since their approval in 2014, …

… discuss their potential clinical implications. Ket Words: PARP, cancer, inflammation, diabetes.
… Data obtained with PARP inhibitors or derived from PARP-1 or PARP-2 knock-out mice …

… of poly(ADP-ribose) polymerase (PARP) for the therapy of various diseases. The first … and
clinical data with PARP inhibitors in various forms of cancer. In this context, the role of PARP in …

… Given the expanding clinical use of PARP inhibitors and the high likelihood of … clinical
strategies to manage PARP inhibitor resistant disease. This review will examine PARP inhibitors in …

… profiles, and it remains to be seen if they have implications for efficacy, biomarker development,
etc. A summary of approved and investigational PARP inhibitors is presented below. …

… We await further clinical data on the implications of mutations at these sites, particularly
with regard to sensitivity to platinum-based agents and the efficacy of PARP inhibitors. …

… We conducted an extensive review of PARP inhibitors using a Medline search. We also
searched abstracts in databases of major international oncology meetings from the last 4 years. …